Mass General Brigham
Health Plan

Antiretroviral Agents
Sunlenca (lenacapavir)
Trogarzo (ibalizumab-uiyk)
Yeztugo (lenacapavir)
Effective 11/17/2025

Plan	☒ MassHealth ☐Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☐ Pharmacy Benefit ☒ Medical Benefit		
Specialty Limitations	N/A		
Contact Information	**Medical Benefit** **Pharmacy Benefit**	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	These medications are also available on the pharmacy benefit. Please see the MassHealth Drug List for coverage and criteria. Additional agents from this class are available through the pharmacy benefit. Please see the MassHealth Drug List for coverage and criteria.		

Overview
Sunlenca, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations.

Trogarzo, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

Yeztugo is a capsid inhibitor that is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating Yeztugo.

Coverage Guidelines
Authorization may be granted for members new to the plan who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.
OR
Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

Sunlenca (lenacapavir)
1. Member has a diagnosis of HIV-1 infection
2. Member is ≥ 18 years of age
3. Member has ongoing detectable viremia (e.g., >200 copies/mL)

4. Member is antiretroviral experienced with documented historical or baseline resistance, intolerability, and/or contraindication to antiretroviral*
5. Failing current antiretroviral regimen due to resistance, intolerance or safety considerations†
6. Concurrent antiretroviral therapy with at least one other antiretroviral
7. Appropriate dosing
8. For Rukobia (fostemsavir), requested quantity is ≤ 2 units/day

*Implies documented history of resistance, adverse reaction, or contraindication to an antiretroviral that is not part of the current regimen.
†Implies documented resistance, adverse reaction, or safety concern with current antiretroviral regimen.

Trogarzo (ibalizumab-uiyk)

1. Diagnosis of HIV-1 infection
2. Member is ≥ 18 years of age
3. Ongoing detectable viremia (e.g., > 200 copies/mL)
4. Resistance to at least one antiretroviral medication from each of three classes of antiretroviral medications (including combination agents): See Appendix B
    a. NRTI (Combivir, Viread, Epivir, etc.)
    b. NNRTI (Edurant, Intelence, Sustiva, etc.)
    c. PI (Prezista, Evotaz, Aptivus, etc.)
5. Concurrent antiretroviral therapy with at least one other antiretroviral
6. Appropriate dosing

Yeztugo (lenacapavir)

1. Diagnosis of pre-exposure prophylaxis (PrEP)
2. Member is HIV-negative
3. Member is considered at-risk for acquiring HIV infection
4. Member weight is ≥ 35 kg
5. Clinical rationale for use of requested agent instead of Apretude (cabotegravir) documented as ONE of the following:
    a. Medical records documenting an allergic reaction to Apretude
    b. Medical necessity for the use of Yeztugo instead of Apretude (e.g., medical necessity supporting the use of an every six-month preparation vs. every two-month preparation)
6. Appropriate dosing

Continuation of Therapy

Resubmission by prescriber will infer a positive response to therapy.

Limitations

1. Initial approvals and reauthorizations will be for 12 months.

Appendix

A. Rationale for combination therapy

- Documentation of significant psychiatric diagnosis (must include specific diagnosis) leading to documented difficulty with adherence
- Homeless members who may have difficulty storing larger amounts of medications (documentation of homelessness on the PA form is sufficient)

- Documented difficulty with adherence leading to complications (low CD4 count leading to infections and/or hospitalizations)
- Child/adolescent member or a member with documented developmental issues without adequate supports to properly manage their own HIV regimen

B. HIV Antiretrovirals by Class

Integrase inhibitor	NRTI	NNRTI	PI	Fusion inhibitor	CCR5 antagonist	Post-attachment inhibitor
Bictegravir	Abacavir	Delavirdine	Atazanavir	Enfuvirtide	Maraviroc	Ibalizumab-uiyk
Cabotegravir	Didanosine	Efavirenz	Darunavir			
Dolutegravir	Emtricitabine	Etravirine	Fosamprenavir			
Raltegravir	Lamivudine	Nevirapine	Indinavir			
	Stavudine	Rilpivirine	Lopinavir			
	Tenofovir		Nelfinavir			
	Zidovudine		Ritonavir			
			Saquinavir			
			Tipranavir			
Attachment Inhibitor	**Capsid inhibitor**					
Fostemsavir	Lenacapavir					

References

1. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1- Infected Adults and Adolescents Living with HIV, 2021 [guideline on the Internet]. 2021 June 3 [cited 2021 Aug 7]. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf.
2. Pre-exposure prophylaxis for the prevention of HIV infection in the United States – 2021 update. Center for Disease Control and Prevention. 2021. Available from: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf.
3. Trogarzo [package insert on the Internet]. Montreal (Canada): Theratechnologies Inc.; 2024 Dec.
4. Sunlenca [package insert]. Forster City (CA): Gilead Sciences, Inc.; 2024 Dec.
5. Yeztugo [package insert]. Forster City (CA): Gilead Sciences, Inc.; 2025 Jun.

Review History

05/19/2021 – Created and Reviewed to match MH UPPL for 7/1/2021
07/19/2021 – Removed Cabenuva from criteria to match with MH UPPL. Effective 02/01/2022.
11/16/2022 – Reviewed and updated for Nov P&T. Matched MH by adding “Drug that require PA vs No PA” table. No clinical changes. Effective 2/1/23.
02/08/2023 - Reviewed and updated for Feb P&T. Matched MH criteria. Updated table in Overview by adding the following drugs requiring PA: Apretude, Cimduo, Selzentry, Symfi/Lo, Temixys, Tivicay, Trogarzo, Viramune XR. Added criteria for the following: Apretude, Cimduo, Selzentry, Symfi/Lo, Tivicay, Trogarzo, Viramune XR. Added appendix. Updated references. Added QLs for Cimduo, Temixys, Tivicay. Effective 4/1/23.
05/10/23 – Reviewed and updated for P&T. Removed brand names Viramune and Viramune XR from the guideline due to obsolete status. Apretude®(cabotegravir injection) to be available dual benefit. Effective 6/5/23.

06/14/23 – Reviewed and updated for P&T. Admin update: clarified that Apretude and Trogarzo are available through pharmacy and medical benefits (dual). Effective 6/30/23
07/12/23 – Reviewed and updated for P&T. New drug, Sunlenca (lenacapavir), was added to policy requiring PA through both benefits. Apretude will be available without PA with preferred drug status. Brand preferred and mandatory generic language was added under Limitations. Effective 7/31/23
12/13/23 – Reviewed and updated for P&T. Formatting update to reflect the removal of preferred status from Prezista. No clinical changes. Effective 1/2/24
05/15/25 – Reviewed and updated for P&T. Updated formatting and references. Removed Rx drugs from medical criteria, Rx is available on MHDL. Sunlenca and Trogarzo remains. Effective 6/1/25
10/8/25 – Reviewed and updated for P&T. Added Yeztugo to MB policy. Drug will be available on pharmacy and medical benefits. Effective 11/17/25